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http://dx.doi.org/10.1016/j.fjs.2012.Summary Introduction: The outcome of stage I colorectal cancer (CRC) patients is excel-
lent. However, even after radical surgery, 10% of patients develop tumor recurrence or metas-
tasis.
Aim: The aim of this study was to evaluate the prognostic significance of clinicopathologic
features to identify high-risk stage I CRC patients.
Methods: A total of 292 stage I CRC patients undergoing curative-intention surgery at Taipei
Veterans General Hospital between 2000 and 2006 were enrolled. The measured end point
was the postoperative disease-free survival (DFS).
Results: Of 292 cases, 185 (63.4%) had tumors of T2 stage, 16 (5.5%) had lymphovascular inva-
sion (LVI), and 68 (23.3%) had a carcinoembryonic antigen (CEA) level of higher than 5 ng/mL.
With a median follow-up period of 60 months (range, 6e130 months), CRC recurred in
23 patients. Overall, 5-year DFS was 88.7% in stage I disease patients. In the univariate anal-
ysis, 5-year DFS of patients with LVI was 52.7%, which was significantly poorer than that of
patients without LVI (90.9%). Patients with a high CEA level or T2 lesion had a poor 5-year
DFS, but the difference did not reach statistical significance. In the multivariate analysis,
the only important independent factor affecting the 5-year DFS was LVI (hazard
ratio Z 4.27; 95% confidence interval: 1.88e9.68; p Z 0.001). In the T1 disease, 5-year DFS
of patients with LVI was 60.0%, significantly poorer than that of patients without LVI (93.4%;
pZ 0.045). In the T2 disease, the difference of 5-year DFS between patients with and without
LVI was more significant (50.5% vs. 85.1%; p Z 0.003).olon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, National Yang-Ming
ov.tw (S.-C. Chang).
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142 S.-C. Chang et al.Conclusion: Stage I CRC patients in this study had an excellent outcome. Prognosis of patients
having tumor with LVI was poor and should receive an aggressive follow-up protocol.
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reserved.1. Introduction
In Taiwan, colorectal cancer (CRC) is the most common
form of cancer and the third leading cause of cancer death.
At present, more than 10,000 new cases of colonic cancer
are diagnosed yearly.1 Approximately 20% of patients will
have stage I colon cancer (T1-2N0M0) at the time of
diagnosis.2,3
There is no doubt that the majority of stage I colon
cancer patients are indeed cured by surgery alone. Also,
the present National Comprehensive Cancer Network
(NCCN) guideline does not recommend the use of adjuvant
chemotherapy for patients with stage I lesions.4 In the
recommendation of post-treatment surveillance, follow-
ups for patients with stage I disease need not be as
frequent as that for patients with stage II or III disease.4
Although the prognosis of stage I disease patients is excel-
lent, about 10% of patients will develop local relapse and
metastatic disease despite an R0 resection.5 Subgroups
with high-risk characteristics for tumor recurrence should
be identified to receive an aggressive follow-up
surveillance.
In this study, we found that lymphovascular invasion
(LVI) was an independent prognostic factor of stage I
disease patients. Stage I disease patients with LVI should
receive an aggressive follow-up protocol.
2. Materials and methods
2.1. Patients and clinical findings
A total of 351 stage I CRC patients who underwent surgery
at Taipei Veterans General Hospital from 2000 to 2006 were
initially screened for enrollment in this study. Prior to
surgery, several surveillance procedures were performed,
including colonoscopy and computed tomography (CT)
scans of the area from the neck to the pelvis. First of all, 13
patients who received preoperative chemoradiotherapy
were excluded from this study. For patients with symp-
tomatic bone pain or high carcinoembryonic antigen (CEA)
levels, whole-body bone scans were performed. All clinical
findings were recorded in detail prospectively and were
stored in computerized files. The database included the
following information: (1) name, gender, age, family
history, and major medical problems; (2) location, size,
gross appearance, stage, differentiation, and important
pathological prognostic features of the tumor; and (3) type
of operation, complications, recurrence, and follow-up
conditions. The disease stage was determined according
to the Tumor-Node-Metastasis (TNM) classification system
of the American Joint Committee on Cancer.6,7 Important
pathological features of the tumors were defined accordingto the consensus statement of the College of American
Pathologists6 and included LVI, and differentiation. After
surgery, patients were monitored every 3 months for the
first 2 years and every 6 months thereafter. At each visit,
imaging studies, including chest radiography and either
abdominal ultrasonography or abdominopelvic CT, were
performed. Colonoscopy was performed every 6 months to
1 year after surgery and every 3 years thereafter.
Unscheduled CT, a whole-body bone scan, or positron
emission tomography was performed for patients with
increased serum levels of CEA or CA19-9 or for symptomatic
patients. Our definition of high-risk factors originated from
the NCCN guidelines,4 including emergency surgery, lym-
phovascular involvement, poorly differentiated histology,
lymph nodes harvested less than 12 in number, and a high
CEA level. Finally, 46 patients were dropped out from this
study, including 24 (7.1%) patients without any follow-up
records, 15 (4.4%) patients whose pathologic records
showed only TNM staging but no microscopic descriptions,
and seven (2.1%) patients without any CEA levels. There-
fore, in total 292 cases were enrolled for the statistical
analysis.
3. Statistical analysis
The statistical end point of the analyses was the disease-
free survival (DFS) from the date of surgery. Group distri-
butions for each clinicopathologic trait were compared
using two-tailed Fisher’s exact procedure and the chi-
square test. Numerical values were compared using
Student t test. Data are expressed as mean  standard
deviation. KaplaneMeier survival curves were plotted and
compared using the log-rank test. A multivariate analysis
was performed using the Cox proportional hazard model.
Statistical significance was defined as p < 0.05. Statistical
analyses were performed using SPSS for Windows version
13.0 software.
4. Results
A total of 292 stage I CRC patients undergoing curative-
intention surgery were enrolled in this study. The patient
population was composed of 184 men (63.0%) and 108
women (37.0%). The mean age at tumor resection was
63.1  10.3 years (range, 22e86 years; median, 64 years).
As regards tumor locations, 159 (54.6%) were colonic and
133 (45.4%) were rectal. The mean lymph node number
harvested was 14.5  8.2 (range, 0e56; median, 12). In 116
cases (39.7%), less than 12 lymph nodes were harvested.
In these 292 cases, 185 (63.4%) had tumors of T2 stage,
16 (5.5%) had LVI, and 68 (23.3%) had a CEA level higher
than 5 ng/mL, and three tumors were poorly
Table 2 Multivariate analysis for 5-year DFS.
Factor 5-year DFS
HR 95% CI p
Tumor depth
T2 vs. T1 1.83 0.88e3.79 0.106
Preoperative CEA level (ng/mL)
>5 vs. <5 1.49 0.76e2.88 0.243
Lymphovascular invasion
Yes vs. no 4.27 1.88e9.68 0.001
Mucinous adenocarcinoma
Yes vs. no 2.27 0.92e3.21 0.074
Tumor infiltrative lymphocyte
No vs. yes 1.27 0.28e1.93 0.532
Tumor border
Infiltrative vs. expansive 1.25 0.47e1.78 0.921
LVI in stage I colon cancer 143differentiated. Twenty-one (7.2%) patients had mucinous
adenocarcinoma and 52 (17.8%) had infiltrative lympho-
cytes in the tumors. No perineural invasion was found in our
series. Only one received emergency operation due to
obstruction. Since the number of cases having emergency
operation and poor differentiation of the tumor was small,
these two factors were excluded in the statistical analysis.
With a median follow-up period of 60 months (range,
6e130 months), CRC recurred in 23 patients (14 cases of
liver metastasis, 10 cases of lung metastasis, and 3 cases of
peritoneal carcinomatosis). Overall, the 5-year DFS was
88.7% in stage I disease patients.
According to a univariate analysis, only LVI affected 5-
year DFS of stage I disease patients significantly. As shown
in Table 1, the 5-year DFS of patients with LVI was 52.7%,
which was significantly poorer than that of patients without
LVI (90.9%). Patients with a high CEA level or T2 lesion had
a poor 5-year DFS, but the difference did not reach statis-





>70 131 87.5 0.212
<70 161 89.7
Gender
Male 184 88.4 0.327
Female 108 89.5
Tumor location
Colon 159 89.2 0.603
Rectum 133 88.4
Tumor depth
T1 107 91.3 0.085
T2 185 83.0
Preoperative CEA level (ng/mL)
<5 224 90.2 0.119
>5 68 79.0
Lymphovascular invasion
No 276 90.9 0.001
Yes 16 52.7
Mucinous adenocarcinoma
No 271 89.5 0.076
Yes 21 79.3
Tumor infiltrative lymphocyte
Yes 52 90.2 0.353
No 240 87.8
Tumor border
Expansive 141 89.2 0.393
Infiltrative 151 87.3
Lymph node harvested
>12 176 89.2 0.715
<12 116 87.8
CEA Z carcinoembryonic antigen; DFS Z disease-free survival.
a Log-rank test.
Tumor location
Rectum vs. colon 1.14 0.61e2.41 0.683
LN harvested
<12 vs. >12 1.24 0.65e2.35 0.508
The p value results from the hypothesis that the HR (as deter-
mined by multivariate binary logistic regression analysis) is 1.0.
CEA Z carcinoembryonic antigen; CI Z confidence interval;
DFS Z disease-free survival; HR Z hazard ratio; LN Z lymph
node.only important independent factor affecting the 5-year DFS
was LVI [hazard ratio (HR) Z 4.27; 95% confidence interval
(CI): 1.88e9.68; p Z 0.001]. Of 107 patients with T1
tumors, five (4.7%) had LVI. Eleven patients with T2 tumors
(5.9%) had LVI. As shown in Fig. 1, in the T1 disease, the 5-
year DFS of patients with LVI was 60.0%, significantly poorer
than that of patients without LVI (93.4%; pZ 0.045). In the
T2 disease, the difference of 5-year DFS between patients
with and without LVI was more significant (50.5% vs. 85.1%;
p Z 0.003).
5. Discussion
Patients with stage I CRC have an excellent prognosis after
oncologic resection, with reported 5-year survival rates of
about 90%.8,9 Our results showed that 5-year DFS of stage I
CRC patients was 88.7%, which was compatible with the
results of previous studies.5,8,9
Based on the evidence from multiple statistically robust
published trials and the fact that these are generally used
in patient management, tumor depth, LVI, and the CEA
level can be classified as Category I prognosticators.
However, we identified only LVI as the independent prog-
nostic factor of the outcome of stage I CRC patients. For
stage I disease, the cause of tumor recurrence or metas-
tasis must be an undetected or undetectable local or
systemic residual of the tumor at operation. Evidence has
emerged showing a significant amount of nodal metastases
of 2 mm or less, likely to be missed during conventional
gross pathological specimen examination.5,10,11 Tumors
Figure 1 The 5-year DFS rate according to status of LVI (blue
line: without LVI; green line: with LVI). (A) In the T1 disease,
the 5-year DFS in patients with and without LVI was 60.0% and
93.4%, respectively. (B) In the T2 disease, the 5-year DFS in
patients with and without LVI was 50.5% and 85.1%, respec-
tively. DFS Z disease-free survival; LVI Z lymphovascular
invasion.
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metastasis. In a previous study, immunohistochemical
assessment showed that LVI was associated with the pres-
ence of micrometastasis in patients with N0 stage.12 Also,
several studies demonstrated that in T1 or T2 CRC, LVI was
the independent predictor of lymph node metastases, as
shown by multivariate analysis.13e15 Recently, a prospec-
tive study demonstrated that primary colon cancer with
extension to the muscularis propria or beyond, LVI, or high
tumor grade correlated with occult metastases in regional
lymph nodes. The possible progression steps are now
established, and LVI plays an important role in the forma-
tion of occult metastasis.15 However, the recent NCCNguideline did not suggest that such stage I CRC patients
should receive chemotherapy. Since the prognosis of stage I
CRC patients with LVI is poor, an aggressive follow-up
should be recommended in such patients.4
Although in our study there was a trend showing that
patients with a T2 lesion or high CEA level had a poor
outcome in the stage I disease, the difference was not
significant. The possible explanation appears to be the
small sample size. To achieve statistical significance sup-
porting the T2 lesion or high CEA level as a prognostic factor
for patients with stage I disease, the estimated minimum
sample size should probably be 1000 or above. The recent
nationwide study from Germany demonstrated that the
impact of the T2 stage is twice that of the T1 stage for
colorectal patients.16
For stage II diseases, several professional organizations
have proposed a minimum node yield of 12 to allow accu-
rate staging.17,18 For stage I disease, recent analysis of
pathological staging from the SEER database suggested that
at least four lymph nodes should be harvested to achieve
a probability of correct staging of 90%.19 In our study, the
mean number of lymph nodes harvested in T1 and T2
disease was 12.3  8.6 and 15.2  10.3, respectively.In
about 40% and 7% of cases, the number of lymph nodes
harvested was less than 12 and 4, respectively. However,
the outcome of these patients was similar to those who had
a higher lymph node harvest with a cutoff value of either 12
or 4 lymph nodes. The number 12 or 4 probably does not
hold any particular biological significance. The true effect
of lymphadenectomy remains debated, as does the
minimum number of nodes necessary for an adequate
resection.20e23 The possible benefit might be more likeli-
hood of actually identifying stage III disease patients or
possibly decreasing local recurrence by resection of
affected lymph nodes.
Although our database was made prospectively, the
study design has limitations associated with its retrospec-
tive nature. About 15% of patients with incomplete data
dropped out from the database. We do not know whether
the inclusion of these cases would have had influenced the
patient outcome statistics. Furthermore, the proportion of
the LVI in stage I disease was only about 6%. We could not
conclude whether stage I CRC patients with LVI should
receive chemotherapy or not.
In conclusion, the stage I CRC patients have an excellent
outcome. However, the prognosis of patients having LVI is
poor and the patients should receive an aggressive follow-
up protocol.References
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